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 Resumé 
Der er i celler med dysfunktionelle mitokondrier (HeLa ρ0) blevet observeret en fænotype 
karakteriseret ved en ubalance i deoxyribonukleotid trifosfat (dNTP) poolsene og et fald i niveauet 
af dNTP pyrimidiner. I sammenhæng hermed blev der også observeret kromosomal ustabilitet. 
Sammenhængen mellem dysfunktionelle mitokondrier og den observerede fænotype er endnu ikke 
klarlagt. DHODHase, der er det fjerde enzym i de novo biosyntesen af pyrimidiner, er blevet 
foreslået som linket herimellem. DHODHase er lokaliseret i den indre mitokondriemembran, og 
dens aktivitet er afhængig af en funktionel elektrontransportkæde. Det er derfor foreslået, at 
dysfunktionelle mitokondrier kan påvirke DHODHase og dermed resultere i den observerede 
fænotype. For at undersøge om det er en inhibering af DHODHase der er involveret i denne 
fænotype, ønskes DHODHase inhiberet ved hjælp af stofferne leflunomid (LFM) og dens aktive 
metabolit A77 1726 in vitro. Formålet var at inkubere en human livmoderhalscancer cellelinje 
(HeLa ρ+) og en osteosarcoma cellelinje uden thymidin kinase aktivitet (143B TK-) med LFM og 
A77 1726, og herefter måle niveauet af dNTP poolsene samt cellecyklusdistribution. På grund af 
tidshorisonten for projektet er en inhibering af DHODHase kun blevet undersøgt i HeLa ρ+ celler 
ved brug af LFM.  
Resultaterne viser, at 21 timers LFM behandling fører til en ubalance i dNTP poolsene samt til et 
fald i dTTP, dATP og dGTP poolsene, hvor dNTP purinerne var mest sensitive. LFM havde 
endvidere en inhiberende effekt på cellecyklusprogressionen, idet andelen af HeLa ρ+ celler i G0/G1 
fasen steg ved LFM behandling. Ændringerne i dNTP poolsene ved behandling med LFM synes 
ikke kun at være associeret med en effekt på cellecyklus, men også at være forårsaget af LFM’s 
effekt på dNTP poolsene.    
På baggrund af dette studie synes en inhibering af DHODHase ikke at være forbundet til et fald i 
dNTP pyrimidinniveauerne, som er observeret i HeLa ρ0 celler, men det kan ikke udelukkes, om en 
mere potent inhibering af DHODHase ved brug af A77 1726 fører til et fald i dNTP 
pyrimidinniveauerne. 
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 Abstract 
In cells with dysfunctional mitochondria (HeLa ρ0) a phenotype characterized by an imbalance in 
deoxyribonukleotid triphosphate (dNTP) pools and a decrease in the levels of pyrimidine dNTP is 
observed. In this context, chromosomal instability was also observed. The relationship between 
dysfunctional mitochondria and the observed phenotype is not yet clear. DHODHase, the fourth 
enzyme in de novo biosynthesis of pyrimidine, has been proposed as the link. DHODHase are 
located in the inner mitochondrial membrane and its activity depends on a functional electron 
transport chain. It is therefore proposed that dysfunctional mitochondria may affect DHODHase and 
results in the observed phenotype. By inhibiting DHODHase in vitro with the two modulators 
leflunomide (LFM) and its active metabolite A77 1726 it can be examined if an inhibition of 
DHODHase is involved in this phenotype. The purpose was to incubate a human cervical cancer 
cell line (HeLa ρ+) and an osteosarcoma cell line without thymidine kinase activity (TK- 143B) with 
LFM and A77 1726 and to measure dNTP pool levels and cell cycle distribution. Because of the 
time frame for this project an inhibition of DHODHase has only been studied in Hela ρ+ cells using 
LFM. 
The results show that 21 hours LFM treatment leads to a dNTP pool imbalance and a decrease in 
dTTP, dATP and dGTP pools. The dNTP purines were most sensitive. LFM did also have an 
inhibitory effect on cell cycle progression, since the percentage of Hela ρ+ cells in G0/G1 phase 
increased by LFM treatment. These differences in the cell cycle distribution do not seem to account 
for the observed changes in the dNTP pool levels in Hela ρ+ cells treated with LFM. 
Based on this study an inhibition of DHODHase does not seem to be the link between the decrease 
in dNTP pyrimidines observed in ρ0 cells. It is not possible to exclude if a more potent inhibition of 
DHODHase by A77 1726 would cause a decrease in the dNTP pyrimidines. 
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 Abbreviations 
10-CHO-TFH 10-formyltetrahydrofolate 
143B Osteosarcoma cells 
143B TK- Osteosarcoma cells without thymidine kinase 
BER Base excision repair 
BQR Brequinar 
CCMP Corrected count per minutes 
CIN Chromosomal instability 
DHO Dihydroorotate 
DHODHase Dihydroorotate dehydrogenase 
DMEM Dulbecco's modified eagle medium 
dNTP Deoxyribonucleotide phosphate 
DR Direct repair 
DTT Ditiotreitol 
EGFR Epidermal growth factor receptor 
ETC Electron transport chain 
FACS Fluorescence activated cell sorter 
FBS Fetal bovine serum 
FMN Flavin mononucleotide 
FMNH2 Dihydroflavin mononucleotide 
HaCaT Human epidermal cells 
HeLa Human cervical cancer cells 
LFM Leflunomide 
MCF12A Breast epithelial cells 
MMR Mismatch repair 
MOLT-4 Human lymphoblastic leukaemia cells 
mtDNA Mitochondrial DNA 
nDNA Nucleus DNA 
NER Nucleotide excision repair 
NTP Ribonucleotide phosphate 
P/S Penicilin/Streptomycin 
VIII 
 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PI Propidium iodide 
PT pore Permeability transition pore 
Q Ubiquinone 
QH2 Ubiquinol 
RER Recombinational repair 
RNase Ribonuclease 
RnR Ribonucleotide reductase 
ROS Reactive oxygen species 
SD Standard deviation 
TLS Translesion synthesis 
ρ+ cells Cells with mtDNA 
ρ0  cells Cells without mtDNA 
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 1 Introduction 
 1.1 Dysfunctional mitochondria 
The mitochondria are involved in several cellular processes e.g. oxidative phosphorylation carried 
out by the electron transport chain (ETC), that are involved in production of ATP reviewed in von 
Kleist-Retzow et al., 2003, regulation of apoptosis reviewed in Birch-Machin, 2006 and the 
production of ribonucleotide phosphates (NTPs) reviewed in Evans & Guy, 2004. The 
mitochondria are present in almost all eukaryotic cells, and most human cells contain 103-104 
mitochondria [reviewed in Cummins, 1998]. The mitochondria have their own DNA (mtDNA), a 
circular 16.5 kbp long genome and each mitochondria contains 2-10 copies of this genome 
reviewed in Penta et al., 2001. The mtDNA is passed on maternally [reviewed in Birch-Machin, 
2006] and encodes 13 of the 90 subunits of the ETC. The additional subunits are encoded by 
nucleus DNA (nDNA). Both functional mtDNA and nDNA are essential for a fully functional ETC 
[reviewed in Lee & Wei, 2007]. 
 
Mutations in mtDNA have now been reported in several cancer types e.g. thyroid, ovarian, salivary, 
liver, lung, kidney, colon, gastric, brain, bladder, head and neck, breast cancer, and leukaemia 
[reviewed in Modica-Napolitano & Singh, 2002; reviewed in Modica-Napolitano & Singh, 2004; 
reviewed in Penta et al., 2001].  
There are several studies that support that the mtDNA and thereby the mitochondria are involved in 
the development of cancer [Kulawiec et al., 2008; Singh et al., 2005]. Kulawiec et al. [2008] have 
made two in vitro experiments and one in vivo experiment, which indicate that a breast epithelial 
cell line without mtDNA (MCF12A 0) has a tumorigenic phenotype. Cells without mtDNA (0) are 
a general model for dysfunctional mitochondria. MCF12A 0 cells can form colonies in soft agar 
medium whereas MCF12A + cells remained as single cells. In addition to this it was shown that the 
MCF12A 0 cells could invade through a porous membrane to a greater extent than the MCF12A + 
cells. Both the formation of colonies in a soft media and an increased invasiveness are two 
characteristic features for a tumorigenic phenotype. It was furthermore demonstrated that injection 
with MCF12A 0 cells and not with MCF12A + cells resulted in tumor formation in mice 
[Kulawiec et al., 2008].  
Singh et al. [2005] have made similar experiments in which three cell types were used, and their 
ability to form colonies on soft agar was examined. The cell types used were osteosarcoma cells 
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(143B +), 143B ρ0 and derived cybrid cells. The cybrid cells are 143B ρ0 cells in which platelets 
have been transferred into in order to ad exogenous wild type (wt) mitochondria. The 143B ρ0 cells 
had an increased ability to form colonies on soft agar plates compared to 143B + cells. The cybrid 
cells suppressed the mutator phenotype [Singh et al., 2005]. This shows that an invasive phenotype 
in ρ0 can be reversed by introduction exogenous wild type (wt) mitochondria.  
It has furthermore been demonstrated that ρ0 cells have been associated with chromosomal 
instability (CIN) [Desler et al., 2007] which is associated with a variety of cancers [Jallepalli & 
Lengauer, 2001].  
 
Several factors can cause mtDNA mutations and thereby dysfunctional mitochondria [reviewed in 
Modica-Napolitano & Singh, 2002; reviewed in Pelicano et al., 2004; reviewed in Penta et al., 
2001 reviewed in Singh, 2004; reviewed in von Kleist-Retzow et al., 2003]. Reactive oxygen 
species (ROS) generated by the ETC can modify the DNA and thereby cause mutations in mtDNA 
reviewed in Penta et al., 2001and nDNA [reviewed in Pelicano et al., 2004]. mtDNA is though 
more affected by ROS than nDNA [reviewed in Pelicano et al., 2004] because nDNA contains 
introns [reviewed in Modica-Napolitano & Singh, 2002; reviewed in Singh, 2004], histones, and 
has a improved repair system. The mitochondrial repair systems are recombinational repair (RER), 
mismatch repair (MMR), base excision repair (BER) and direct repair (DR), whereas the nDNA 
have more repair mechanisms [reviewed in Larsen et al., 2005]. Mutations in specific parts of the 
nDNA, that normally maintain mtDNA stability, can also cause mtDNA mutations in particular 
deletion or depletion [reviewed in von Kleist-Retzow et al., 2003].  
 
Dysfunctional mitochondria have been demonstrated to cause a depolarization of the mitochondrial 
membrane. XTC.UC1 cells, a human thyroid carcinoma cell line, with a defect complex I was 
treated with the complex III inhibitor antimycin A. This treatment resulted in a depolarization of the 
mitochondrial membrane. It was furthermore demonstrated that the ATP synthesis was decreased in 
the XTC.UC1 cells when substrates for complex I were used Porcelli et al., 2009. 
 1.2 Dysfunctional mitochondria can cause an imbalance in the 
dNTP pools and thereby mutations 
The mitochondria are partly involved in the biosynthesis of NTPs [Chen & Jones, 1976]. There are 
two pathways in the cell that lead to biosynthesis of nucleotides. The de novo pathway also called 
the de novo biosynthesis and the salvage pathway [Rückemann et al., 1998]. In the de novo 
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biosynthesis purine and pyrimidines are synthesised from their metabolite precursors ribose 5-
phosphate, CO2, amino acids, and NH3. The salvage pathway is a pathway that recycles the free 
bases and nucleosides released from the breakdown of RNA and DNA [Nelson & Cox, 2005, p. 
862]. The mitochondria are linked to the de novo biosynthesis of pyrimidines through the enzume 
dihydroorotate dehydrogenase (DHODHase) [Bader et al., 1998; Davis et al., 1996; Löffler et al., 
1997; Rawls et al., 2000]. 
In the de novo biosynthesis of pyrimidines is UMP synthesized. UMP can be converted into UTP 
and CTP in several different enzyme catalysed reactions and finally to dTTP and dCTP [Rückemann 
et al., 1998]. The ribonucleotides are reduced to the corresponding deoxyribonucleotides by the 
enzyme ribonucleotide reductase (RnR) in the de novo biosynthesis of dNTPs [reviewed in 
Reichard, 1988].  
Cellular dNTP is distributed between two different pools, the cytosolic and the mitochondrial pools 
reviewed in Mathews & Song, 2007. The mitochondrial dNTP pools only constitute 1/10 of the 
total amount of the dNTP pools in proliferating human wt cells Desler et al., 2007. The size of the 
cytosolic dNTP pools vary through cell cycle, and there are a high increase in all four dNTP pools 
during the transition from G1 to S phase [Nicander & Reichard, 1983; reviewed in Traut, 1994], for 
which reason the size of the dNTP pools are elevated in proliferating cells. In addition to this it 
should be noted that the dNTP pool levels varies between different cell lines [reviewed in Traut, 
1994]. 
 
Dysfunctional mitochondria have been demonstrated to be associated with an imbalance in the total 
dNTP pool levels Desler et al., 2007. Desler et al. [2007] have reported that human cervical cancer 
cells devoid of mtDNA (HeLa0) have a decreased level of dNTP pyrimidines compared with 
HeLa + cells. The dTTP and the dCTP levels were decreased 5-6 fold in HeLa 0 cells compared 
to HeLa + cells. Contrary to this, the dATP and the dGTP levels did not change in HeLa 0 cells 
compared with HeLa + cells Desler et al., 2007.  
This association between dysfunctional mitochondria and an imbalance in the dNTP pools can have 
fatal consequences, because a balanced supply of dNTPs is necessary for a proper function of the 
replication and repair mechanisms of DNA reviewed in Reichard, 1988; Wickremasinghe & 
Hoffbrand, 1980otherwise mutations can occur [Song et al., 2003; reviewed in Reichard 1988; 
Bebenek & Kunkel, 1990].  
An imbalance in the cytosolic dNTP pools induced by the drug JCI-3661 that interferes with RnR 
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caused DNA double-strand breaks in mouse mammary tumor FM3A cells Yamato et al., 1992. 
CIN was observed in cells with dysfunctional mitochondria (HeLa 0 cells) in addition to an 
imbalance in the dNTP pool levels [Desler et al., 2007]. It was also demonstrated that a cytosolic 
dNTP pool imbalance induced by the drug hydroxyurea, that inhibits RnR, in human lymphocytes 
caused a delay in the replication fork Wickremasinghe & Hoffbrand, 1980.  
 1.3 The pyrimidine synthesis is linked to the mitochondria by 
DHODHase  
The mechanisms underlying the interrelation between the mitochondria and the regulation of the 
dNTP pools are still unknown [Desler et al., 2007]. It is conceivable that dysfunctional 
mitochondria impair the nucleotide biosynthesis by interfering with the mitochondrial enzyme 
DHODHase [reviewed in Singh et al., 2004]. This hypothesis that connects dysfunctional 
mitochondria to the regulation of dNTP pools via DHODHase has not been supported by 
experimental evidence so far. 
 1.3.1 DHODHase 
DHODHase is localised before complex III in the ETC [Löffler et al., 1997] and catalyzes the 
oxidation of dihydroorotate (DHO) to orotate by transferring electrons to the ETC molecule 
ubiquinone (Q) through an enzyme-bound redox cofactor flavin mononucleotide (FMN) [Rawls et 
al., 2000]. This redox reaction is divided into two steps. DHO is oxidized to orotate while FMN is 
reduced to dihydroflavin mononucleotide (FMNH2) in the first step. FMNH2 is reoxidized to FMN 
while Q is fully reduced to ubiquinol (QH2) in the second step (figure 1) [Bader et al., 1998]. The 
orotate synthesized by DHODHase is converted to UMP by the enzyme complex UMP synthase 
[Löffler et al., 1997]. 
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Figure 1 The fourth enzymatic step in the de novo biosynthesis of pyrimidines is catalyzed by DHODHase that is 
located in the inner mitochondrial membrane. Dihydroorotate (DHO) is oxidized to orotate by DHODHase while 
FMN is reduced to dihydroflavin mononucleotide (FMNH2). FMNH2 is thereafter reoxidized to FMN while Q is 
fully reduced to ubiquinol (QH2) [revised from Rawls et al., 2000, p. 2085].  
 
The human DHODHase has two domains, an α/β-barrel domain and an α-helical domain. The first 
domain contains the active site where FMN is located and the second domain forms the tunnel 
opening for Q leading to the active site where Q is reduced to QH2 [Liu et al., 2000].  
The import of DHODHase into the inner mitochondrial membrane depends on an intact N-terminus 
of DHODHase.  This N-terminus contains a cationic and hydrophobic region that is essential for the 
submitochondrial localization of the protein. The import of DHODHase also requires ATP and a 
inner mitochondrial membrane potential [Rawls et al., 2000].  
A proper function of DHODHase depends on electrons from the ETC. Therefore any dysfunction of 
the ETC would induce an impairment of the de novo biosynthesis. Any dysfunction of the ETC 
could e.g. be caused by hypoxia, ETC inhibitors that result in QH2 build up, and inherited or 
acquired defects of complex III or IV in the ETC. This impairment of DHODHase would be 
reflected by a decrease in UMP synthesis [Löffler et al., 1997].  
 1.3.2 Inhibition of DHODHase causes an imbalance in the levels of NTP 
and dNTP pools 
Several inhibitors of DHODHase have been demonstrated e.g. brequinar (BQR) and the active 
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metabolite of leflunomide (LFM) A77 1726 [Knecht & Löffler, 2000; Knecht et al., 2000].   
The immunosuppressive prodrug LFM is converted in vivo to A77 1726 e.g in microsomes by some 
cytochrome P450 enzymes [Bartlett et al., 1991; Kalgutkar et al., 2003].  
Greene et al. [1995] were the first to demonstrate that A77 1726 inhibits DHODHase. Several 
studies have shown that A77 1726 interferes with the second step of the redox reaction where the 
cofactor FMNH2 is reoxidized to FMN while Q is reduced to QH2 (figure 2) [Bader et al., 1998; 
Davis et al., 1996]. In addition to this it has been demonstrated, that A77 1726 is a noncompetitive 
inhibitor of the Q binding site and an uncompetetive inhibitor in respect to binding of DHO [Knecht 
& Löffler, 1998; Knecht & Löffler, 2000]. Though, Davis et al. [1996] have reported that A77 1726 
was a competitive inhibitor of Q and a noncompetitive inhibitor of DHO [Davis et al., 1996].  
BQR is another immunosuppressive drug that inhibits the second step in the reaction catalyzed by 
DHODHase [Chen et al., 1992; Cherwinski et al., 1995b; Rawls et al., 2000; Rückemann et al., 
1998]. BQR has both been demonstrated to be a competitive [Knecht & Löffler, 2000] and a 
noncompetitive inhibitor with respect to Q [Copeland et al., 1995], and a noncompetitive inhibitor 
of DHO [Copeland et al., 1995]. 
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Figure 2 The fourth enzymatic step in the de novo biosynthesis of pyrimidines is catalyzed by DHODHase. The 
second step of the redox-reaction catalyzed by DHODHase is inhibeted by the two drugs A77 1726 and brequinar 
(BQR) [revised from Rawls et al., 2000, p. 2085].  
Both A77 1726 and BQR interfere with the second step in the redox reaction catalyzed by 
DHODHase (figure 2) but the enzyme kinetics reported for the two compounds are different [Davis 
et al., 1996; Chen et al., 1992, Greene et al., 1995; Knecht & Löffler, 1998; Knecht et al., 1996]. Liu 
et al. [2000] have demonstrated that BQR and A77 1726 bind to the same site in the α-helical tunnel 
near FMN but A77 1726 has fewer binding sites than BQR because it is smaller and the binding 
region in A77 1726 is less ordered [Liu et al., 2000]. Though, BQR is found to be more potent than 
A77 1726 with respect to inhibition of cell proliferation and inhibition of DHODHase [Greene et 
al., 1995; Knecht & Löffler, 1998]. 
 
A77 1726 and BQR have been demonstrated to have an antiproliferative effect that can be reversed 
by addition of uridine or cytosine [Cherwinski et al., 1995a; Silva et al., 1997; Rückemann et al., 
1998; Nair et al., 1995; Williamson et al., 1995; Zielinski et al., 1995]. The cells incubated with A77 
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1726 or BQR accumulated in the G1 phase and early S phase, and the progression from the S phase 
to the G2/M phase was inhibited [Cherwinski et al., 1995a; Greene et al., 1995; Rückemann et al., 
1998].  
Cherwinski et al. [1995b] have reported that A77 1726 decreases the CTP and UTP level in 
proliferative human T lymphoblast cells in vitro. The CTP and UTP levels were decreased by 73±4 
% and 84±3 % when the T lymphoblast cells were incubated for 18 hours with 100 µM A77 1726. 
The CTP and UTP levels were decreased by 51±17 % and 58±22 % respectively when incubated 
with 10 µM A77 1726. The A77 1726 treatment did not change the ATP and GTP level notable 
[Cherwinski et al., 1995b]. 
Incubation with 10 µM BQR for 18 hours decreased the CTP and UTP level by 76 % and 86 % in 
the same kind of cells. Contrary to the effect of A77 1726, 10 µM BQR affects the NTP purine 
levels as it reduces the ATP level by 60 % and increases the GTP level by 25 % [Cherwinski et al., 
1995b].    
Rückemann et al. [1998] have made similar experiments and demonstrate that BQR (0.5 or 1.0 µM) 
and A77 1726 (25, 50 or 100 µM) decrease the NTP pyrimidine levels in proliferative human T 
lymphocytes and human peripheral blood mononuclear cells (PBMC). Contrary to Cherwinski et al. 
[1995b] Rückemann et al. [1998] demonstrate that 100 µM A77 1726 also has an effect on the NTP 
purine levels because it decreases the level by 50 %. The effect of BQR and A77 1726, except the 
100 µM concentration of A77 1726, could be reversed by preincubation with uridine. It was 
furthermore demonstrated by Rückemann et al. [1998], that radiolabeled incorporation of [14C] 
Bicarbonate into UTP and CTP was completely blocked by A77 1726 and BQR and it was not 
reversed by addition of uridine. The incorporation of [14C] Bicarbonate into ATP and GTP was also 
reduced by A77 1726 and BQR in connection with theirs antiproliferative effect. The incorporation 
of [14C] Bicarbonate into ATP and GTP could on the other hand be reversed by addition of uridine. 
Together this support that the de novo biosynthesis of pyrimidines is blocked by A77 1726 and BQR 
even though the cell proliferation was normalised and all NTP pools were restored by addition of 
uridine [Rückemann et al., 1998]. 
  
The effect of BQR has also been studied in relation to the levels of the dNTP pools. Human 
lymphoblastic leukaemia cells (MOLT-4) were exposed to 5 µM BQR for 5 hours. When treated 
with BQR the dTTP, dCTP and dGTP pool levels decreased. The decrease compared to the control 
for the different dNTPs were 112.1 pmol/106 cells vs. 64.9 pmol/106 cells for dTTP, 18.9 pmol/106 
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cells vs. 14 pmol/106 cells for dCTP and 24.7 pmol/106 cells vs. 14.7 pmol/106 cells for dGTP. The 
dATP pool level was on the other hand increased when the cells were treated with BQR compared 
to the control 49.9 pmol/106 cells vs. 60.4 pmol/106 cells Ahluwalia et al., 1996.  
The effect of BQR and A77 1726 on the NTP and dNTP pools are summarized in table 1. 
Table 1 BQR and A77 1726’s effect on NTP and dNTPs [Ahluwalia et al., 1996; Cherwinski et al., 1995b; 
Rückemann et al., 1998].     
 CTP ATP GTP  UTP dCTP 
(pmol/106 
cells) 
dATP 
(pmol/106 
cells) 
dGTP 
(pmol/106 
cells) 
dTTP 
(pmol/106 
cells) 
BQR -76% 
(10M) 
-60% 
(10M) 
+25% 
(10M) 
-86% 
(10M) 
18.914 
(5M) 
49.9 60.4 
(5M) 
24.7 14.7 
(5M) 
112.164.9 
(5M) 
A77 1726 -51±17% 
(10M) 
-73±4% 
(100M) 
  -58±22% 
(10M) 
-84±3% 
(100M) 
    
 1.3.3 The aim of this study 
Cells with dysfunctional mitochondria have been associated with an imbalance in the dNTP pools 
characterized by a decrease in the dNTP pyrimidine pools. Inhibitors of DHODHase have been 
demonstrated to cause an imbalance in the NTP and dNTP pools in different cell lines (table 1). 
Therefore the aim of this study is to examine if there is a correlation between an inhibition of 
DHODHase and the phenotype observed in cells with dysfunctional mitochondria. This is done by 
treating different cell lines with the prodrug LFM and its active metabolite A77 1726. The cell lines 
used are HeLa + cells and 143B cells that lack thymidine kinase activity (143B TK-). It is possible 
to exclude the dNTP pyrimidines produced from the salvage pathway by including the 143B TK- 
cell line, since this thymidine kinase is only involved in the salvage pathway of pyrimidines. It is 
furthermore examined if LFM and A77 1726 affects a particular phase of the cell cycle.  
The total dNTP pool levels are measured by dNTP radio assay, and the cell cycle distribution is 
measured by fluorescence activated cell sorter (FACS) analysis. This is done with addition of 
different concentrations of LFM and A77 1726 respectively.  
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 2 Materials and methods 
 2.1 Cell handling 
 2.1.1 Cell cultivating 
The cells are obtained from two different human cell lines, a cervical cancer cell line (HeLa wt) and 
an osteocarcoma 143B cell line lacking thymidine kinase (143B TK-). The cells have been grown in 
a 75 cm2 or 175 cm2 flask containing 15 mL or 35 mL growth media respectively. The growth 
media contained 89 % of Dulbecco’s Modified Eagle Medium (DMEM) with Glutamax 
(Intvitrogen, GIBCO), 10 % fetal bovine serum (FBS, BioChrom AG), and 1 % 
Penicillin/Streptomycin (P/S, Invitrogen, GIBCO). The cells were incubated at 37 °C in a 
humidified atmosphere with 5 % CO2 and were routinely passaged to ensure confluency not 
exceeding 70%. Cells were removed by trypsin treatment and cell concentration was determined in 
Z2 Coulter Counter (Beckham Coulter). 
 2.1.2 LFM preparation and LFM incubation 
In this study LFM and the active metabolite of LFM A77 1726 were supposed to be used as a 
modulator of DHODHase. Because of the time frame for the present study the experiments were 
only carried out with LFM and not with A77 1726.  
HeLa + and 143B TK- cells were seeded in 175 cm2 flasks (2.106 cells per flask) and incubated for 
24 hours reaching a confluency of 40%. The cells were incubated for 21 hours in growth media or 
growth media containing either 5, 50 or 100 µM of LFM after which they were prepared for dNTP 
pool determination by dNTP radio assay or determination of cell cycle distribution by FACS 
analysis. 
LFM (Sigma-Aldrich) was stored at 4 °C. The stock solution of 3500 μM LFM was made by 
dissolving 18.914 mg of LFM in 20 mL PBS (Phosphate Buffered Saline, Biowithtaker, Lonza). 
Prior to treatment with LFM the cells in the 175 cm2 growth flasks were washed with 10 mL PBS. 
The volumes of LFM stock solution and growth media, to achieve the wanted concentrations of 
LFM on 5, 50 and 100 μM in the 175 cm2 growth flasks, are listed in table 2. The incubation period 
with LFM was 21 hours. 
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Table 2 Volumes of the LFM stock solution and growth media to achieve the LFM concentrations 5, 50 and 100 
μM. 
LFM concentration in growth flask (μM) Stock solution LFM (mL) Growth media (mL) 
5 0.05 34.95 
50 0.5 34.5 
100 1 34 
 2.2 The principles of the dNTP radio assay 
The measurement of dNTP pools are based on a dNTP radio assay (a DNA polymerase radio assay) 
originally developed by Solter & Handschumacher [1969] and further improved by Sherman & 
Fyfe [1989] and Desler et al. [2007].  
This dNTP radio assay is based on the incorporation of radioactive labelled dNTP by a Klenow 
fragment, that acts as a DNA polymerase, into known oligonucleotide template primers for different 
dNTP determinations. The advantages of this dNTP radio assay are that it is more sensitive and 
requires fewer types of equipment than HPLC [Sherman & Fyfe, 1989].  
Templates for the different dNTP determinations have the same primer (marked with yellow in table 
3). For the dTTP, dCTP and dGTP determinations are radioactive labelled dATP ([3H]-dATP) 
incorporated opposite of the thymidine (marked with a red T in table 3) on the oligonucleotide 
templates. For dATP determination, the radioactive labelled dTTP ([3H]-dTTP) is incorporated 
opposite of the adenosine (marked with a green A in table 3) on the oligonucleotide template.   
In the case of dTTP determination the ratio between radioactive labelled adenosine and unlabelled 
thymidine is 2:1. For the dATP, dCTP and dGTP determinations the ratio between radio labelled 
dNTP and the unlabelled dNTP is 3:1 [Sherman & Fyfe, 1989]. 
Table 3 Template sequences for oligonucleotide templates for the different dNTP determinations. The primer is 
shown in yellow. The thymidines (T) that [3H]-dATP can bind to in the template is in red and the adenosine (A) 
that [3H]-dTTP can bind to is in green. The ratio between the radio labelled and unlabelled is 2:1 for dTTPs and 
3:1 for the dCTP, dGTP and dATP [revised from Sherman & Fyfe, 1989]. 
dNTP 
determination 
Oligonucleotide  Ratio  
dTTP 
 
         5'- TTATTATTATTATTATTA-GGCGGTGGAGGCGG-3' 
                              3'- CCGCCACCTC CGCC-5'  
2:1 
dCTP 
 
5'- TTTGTTTGTTTGTTTGTTTG-GGCGGTGGAGGCGG-3'  
3'- CCGCCACCTC CGCC-5' 
3:1 
dGTP 
 
5'- TTTCTTTCTTTCTTTCTTTC-GGCGGTGGAGGCGG-3'  
                                                 3'- CCGCCACCTC CGCC-5'  
3:1 
dATP 5'- AAATAAATAAATAAATAAAT-GGCGGTGGAGGCGG-3' 
                                               3'- CCGCCACCTC CGCC-5'  
3:1 
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 2.2.1 Preparation for dNTP radio assay 
Cell preparation  
2106 cells, treated with different concentrations of LFM, were centrifuged at 750 g for 5 minutes at 
4 °C and resuspended in 1 mL 60 % methanol. The suspension was incubated at -20 °C for 90 
minutes and then placed in a heating block (Stuart) and boiled at 100 °C for 3 minutes to remove 
enzyme activity. The suspension was then centrifuged at 17,000 g for 15 minutes at 4 °C to isolate 
the dNTPs in the supernatant. The supernatant was frozen in liquid nitrogen. 
 
Oligonucleotides 
The oligonucleotides which are template primers used in the DNA synthesis were made by adding 
380 µL ultrapure water to four 2 mL tubes. Hereafter 10 µL Universal primers (Invitrogen) were 
added to each tube. Finally 10 µL of either dTTP, dATP, dCTP or dGTP DNA primers (Invitrogen) 
were added to one of the E-tubes. The four E-tubes with the samples were set on 70 C for 10 
minutes in a heating block and thereafter cooled down slowly. After around 5-6 hours the four 
oligonucleotides reached room temperature and were stored at -20 C until use.  
 
Klenow buffer 
The Klenow Buffer solution contains 500 mM Tris-HCl, miliQ water, 50 mM MgCl26H2O, 10 mM 
DTT (fermentas.com) where pH was adjusted to 8.0 by addition of NaOH. The Klenow Buffer was 
kept on -20 C until use. 
 
Radioactive dATP and dTTP 
For the 100 µL reaction mix the concentrations were 0.0201 µM [3H]-dATP and 0.0205 µM [3H]-
dTTP. The concentrations were made by use of the stock solutions 0.66 µM [3H]-dATP (17.4 
Ci/mmol, Moravek) and 0.66 µM [3H]-dTTP (27 Ci/mmol, Moravek ) and by adding 3 µL of [3H]-
dATP and 3.1 µL of [3H]-dTTP to two different tubes one for each solution. The two tubes where 
then evaporated with a vacuum pump (Thermo Savant SPD1010 SpeedVac Concentrator, Thermo – 
Electron Corporation). The [3H]-dATP pellet was resuspended in 15 µL ultrapure water and the 
[3H]-dTTP pellet was resuspended in 5 µL. Both suspensions were put on ice. 
 
Tube and paper disc preparation 
Reaction mixture tubes and the Whatman DE81 paper discs were provided with proper markings. 
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For the determination of e.g. dTTP level in one sample three Whatman DE81 paper discs were 
prepared. In order to determine standard curves for dTTP, dCTP, dGTP and dATP were 0, 2, 5 and 
10 pmol of each dNTP used as known concentrations.  
 2.2.2 The procedure for dNTP radio assay 
Before initiation of the DNA polymerase reaction pre reaction mixtures for each sample (dTTP, 
dATP, dGTP and dCTP) were made. The pre reaction mixtures had a total volume of 85 µL and 
contained 64.9 µL ultrapure water, 5 µL of 5 µM template oligonucleotide (dTTP, dCTP, dGTP or 
dATP), 1 u Klenow fragment (Fermentas), 50 mM Tris-HCl (pH=8.0), miliQ water, 5 mM 
MgCl26H2O, 1 mM DTT and 0.0201 µM [3H]-dATP. For the dATP reaction mixture the radioactive 
[3H]-dATP was replaced by 0.0205 µM [3H]-dTTP. The pre reaction mixtures were kept on ice. 
The methanol added to the cell samples as described in section 2.2.1 ‘Preparation for dNTP radio 
assay’ was evaporated with the vacuum pump. The residues were rehydrated in 300 µL ultra pure 
water. The DNA polymerase reaction was initiated by addition of either 15 µL cell extract or 15 µL 
of the standard solutions for the standard curves and incubated in a 37 °C warm water bath for 30 
minutes.  
 
After the incubation period 10 µL of each reaction mixture was spotted three times on the matching 
Whatman DE81 paper discs. The Whatman DE81 paper discs were covered and dried over night in 
dark. The dried Whatman DE81 paper discs were washed three times for 10 minutes with a 5 % 
Na2HPO4 solution (50 g/L) and finally washed with milliQ water. This was done to remove the 
surplus radioactive dTTP and dATP that had not bound to the oligonucleotides. 
For control 10 µL of the standard solutions were spotted to Whatman DE81 paper discs and not 
washed. In case of a similar radioactivity measurement between the control samples and the washed 
samples it could indicate that the procedure was not done properly.  
The paper discs were dried on a tissue and each transferred to a scintillation tube where 0.5 mL of 
eluent (0.1 M HCl and 0.2 M KCl) was added to each tube. The tubes were shaken for 30 minutes 
in order to release as much of the radio labelled oligonucleotide template from the Whatman DE81 
paper discs as possible and thereby increase the sensitivity of the assay. Afterwards 2.5 mL of 
Ultima Gold (Perkin Elmer) was added under a hood in order to prepare the samples for measuring 
the radioactivity. The lid of each tube was closed and mixed by inverting 10-15 times. The samples 
were measured with a 1219 Rackbeta liquid scintillation counter (WALLAC) in corrected counts 
per minute (CCPM). 
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 2.3 Principles of FACS analysis 
Fluorescence activated cell sorter (FACS) analysis is an analysis based on flow cytometry 
measurement. The FACS analysis is used to measure DNA content and cell size to determine cell 
cycle distribution according to the method by Deitch et al. 1982. 
The cellular DNA content varies during the cell cycle, and it is synthesized in the S phase. The 
DNA content in G0/G1 phase cannot be distinguished. When the cells are in the M phase they have 
the same DNA content as in the G2 phase, therefore these phases cannot be distinguished either 
[Nunez, 2001]. The cell cycle distribution of the cells was assayed using the fluorescence marker 
propidium iodide (PI)-stained nuclei. PI can intercalate into both double-stranded RNA and DNA. 
Ribonuclease (RNase) is added to ensure that only DNA is measured and not RNA [Deitch et al., 
1982]. 
 2.3.1 Preparation for FACS analysis 
Cell preparation 
106 cells, treated with different concentrations of LFM, were pelleted by centrifugation at 300 g for 
5 minutes at 4 °C and was resuspended in 10 mL PBS and centrifuged again. The pellet was 
resuspended in 5 mL PBS and was transferred to two FACS tubes in order to make duplicates of the 
same cell sample. PBS was added to the FACS tubes until a final volume of 3 mL was reached. 
These samples were centrifuged at 300 g for 5 minutes at 4 °C and the pellet was resuspended in 
200 μL PBS. 2 mL of 70 % ice cold ethanol was slowly added and mixed in order to fixate cells. 
Cells were incubated for 30 minutes on ice and stored at -20 °C after incubation. 
 2.3.2 The procedure for FACS analysis  
The prepared cell samples for FACS analysis obtained as described in section 2.3.1 ‘Preparation for 
FACS analysis’ were centrifuged at 300 g for 5 minutes at 4 °C in order to pellet the cells. The pellet 
was resuspended in 3 mL PBS and centrifuged again and resuspended in 200 μL PBS, and 50 μL of 
RNAse (1 mg/mL) and 50 μL of PI (0.4 mg/mL). Cell solution was incubated at room temperature 
in dark for 30 minutes.  
The cell cycle distribution was measured with a BD FACSCalibur™ Flow Cytometer (Becton 
Dickinson) after the incubation period. Cell QuestPro software and ModFit.LT program were 
subsequently used for data processing.  
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 2.4 Statistic analysis 
Kolmogorov-Smirnov test was used to test if the dNTP pool level data were normal distributed. The 
measured dNTP pools were found to be normal distributed. The data from the FACS analysis were 
found to be normal distributed based on visualizing a bell shaped distribution of the cells. The 
differences between the level of dNTP pools and cell cycle distribution in untreated HeLa + cells 
(0 M) and in HeLa + cells treated with different concentrations of LMF (5, 50 and 100 M) were 
therefore compared by using the Student T-test. 
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 3 Results 
The aim of the experiments was as described in section 1.3.3 ‘The aim of this study’, to determine 
the dNTP pool levels and cell cycle distribution in HeLa + and in 143B TK- cells incubated with 
different concentrations of LFM (0, 5, 50, 100 M) and A77 1726 (0, 5, 50, 100 M). The 
determination was planned to be done in three independent replicates for both the LFM and A77 
1726 treated cells and four independent replicates for the controls. The cells were though infected 
twice and therefore all these independent replicates were not obtained. The source of infection was 
examined by checking the FBS, P/S, growth media, trypsin_EDTA, PBS and the incubator but it 
gave no positive result for the source of infection.  
The obtained results were four independent replicates for both the HeLa + and the 143B TK- 
controls, and one HeLa + cell replicate for each LFM concentration 0, 5, 50 and 100 M 
respectively. It was not possible to obtain further results due to the time frame. 
 3.1 dNTP pool levels  
The purpose of determining the dNTP pool levels in the cell lines used was to examine if 
DHODHase modulators causes an imbalance in the dNTP pool levels and a decrease in the dNTP 
pyrimidines comparable to the phenotype in cells with dysfunctional mitochondria (HeLa ρ0 cells).  
 
An exact determination of the dNTP pool levels requires that the ratio between the eluent and the 
Ultima Gold are the same in all samples [Personal communication Munch-Petersen, 2009]. Instead 
of adding 0.5 mL of the eluent to all the dNTP samples, the volume increased throughout the 
procedure to a final volume of 0.8 mL. This means that throughout the procedure the volume 
increased by 0.3 mL. Therefore the dNTP pool level determinations for all the cell samples are not 
exact.  
It should furthermore be noted that the one obtained replicate treated with different concentrations 
of LFM (one cell sample per concentrations and) are considered as three independent replicates for 
each concentration of LFM. Since the three Whatman DE81 paper discs are spotted with the same 
cell sample as described in section 2.2.2 ‘The procedure for dNTP radio assay’ they are not three 
independent replicates but three pseudo replicates. The reason why the three pseudo replicates are 
considered as independent replicates is in order to compare the effect of different LFM 
concentrations to the untreated cell samples by students T-test. 
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 3.1.1 CCPM values and standard curves for dNTP pool determinations  
The radioactivity of the cell samples for the dNTP measurement was measured by a 1219 Rackbeta 
liquid scintillation counter in CCPM. The CCPM values for the HeLa + cells treated with different 
concentrations of LFM are shown in figure 3. The CCPM values are converted to pmol/106 cells by 
use of the standard curves in figure 4 and 5. In appendix b.a ‘Calculation from CCPM to pmol/106 
cells’ are the CCPM measurements and an example of how to convert the CCPM values to pmol/106 
cells.  
 
Figure 3 Mean value±standard deviation (SD) for dTTP, dATP, dCTP and dGTP pool levels measured in CCPM 
for HeLa + cells treated with different concentrations of LFM (0, 5, 50, 100 µM) (n=1, but treated as three 
replicates). 
The standard curves in figure 4 are used to determine the dNTP pool levels in HeLa + controls. 
The standard curves in figure 5 are used to determine the dNTP pool levels in 143B TK- controls 
and in the HeLa + cells treated with different concentrations of LFM. The two set of standard 
curves are made in the same assay as the cell samples they are applied for, and are therefore made 
under the same circumstances. 
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Figure 4 Standard curves for dTTP, dATP, dCTP and dGTP for HeLa + controls. 
 
Figure 5 Standard curves for dTTP, dATP, dCTP and dGTP for 143B TK- controls and HeLa + cells treated 
with different concentrations of LFM. 
Based on the design of the dNTP radio assay the CCPM values for the cell samples should be in the 
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range of the standard curves. This is also the case for all the cell samples with the exception of 
dATP determinations for the HeLa + control and the HeLa + cells treated with 0 and 5 µM LFM. 
 3.1.2 dNTP pool levels in HeLa + and 143B TK- controls 
The dNTP pool size order in the HeLa + controls was dCTP, dATP, dGTP and dTTP and for the 
143B TK- controls the order were dGTP, dATP, dCTP and dTTP. The dTTP was the smallest for 
both cell lines. As it appears from table 4 the two cell lines did not have the same distribution or 
dNTP pool sizes. 
Table 4 Levels of dTTP, dATP, dCTP and dGTP pools in HeLa + and 143B TK- controls. The values in this table 
are calculated from the standard curves made in the same assay (figure 4 and 5) (n=4). 
                   dNTP  
Sample 
dTTP  
(pmol/106 cells) 
dATP  
(pmol/106 cells) 
dCTP  
(pmol/106 cells) 
dGTP  
(pmol/106 cells)  
HeLa ρ+ (control)  35.6±9.6** 185.7±59.4 237.3±84.5 36.8±14.9 
143B TK- (control)  39.5±17.1 72.9±20.7 52.4±11.6 92.5±24.2 
** Mean value±SD. 
 3.1.3 dNTP pool levels in HeLa + cells treated with different 
concentrations of LFM  
The aim of treating the HeLa + cells with different concentration of LFM was to investigate if 
LFM had an affect on the dNTP pool levels by an inhibition of DHODHase and thereby to cause a 
dNTP imbalance characterized by a decrease in the dNTP pyrimidines as described in section 1.3.2 
‘Inhibition of DHODHase causes an imbalance in the levels of NTP and dNTP pools’. 
According to table 4 and 5 it is demonstrated that the order and the sizes of the different dNTP 
pools in HeLa + controls and HeLa + cells (0 μM) are not the same as they were supposed to. The 
LFM treated HeLa + cells are therefore compared to the HeLa + cells (0 μM) and not to the HeLa 
+ controls.  
The data in table 5 and figure 6 demonstrates that LFM affects the dNTP pools in HeLa + cells. 
The dTTP pool level in cells treated with 100 µM LFM decreased 2.4 fold (p=0.024) compared to 
HeLa + cells (0 μM). The dATP pool level decreased 1.4 fold (p=0.013) at 50 µM and 2.1 fold 
(p=0.004) at 100 µM LFM. The dGTP pool level decreased 1.6 (p=0.002), 1.8 (p=0.006) and 1.6 
(p=0.008) fold at 5, 50 and 100 µM LFM respectively compared to HeLa + cells (0 μM). The 
dCTP pool was not affected at any concentrations of LFM. This indicates that LFM causes an 
imbalance in the dNTP pools. The dNTP purines are more sensitive to LFM treatment than dNTP 
pyrimidines based on the fact that they were affected at lower concentrations. 
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Table 5 dTTP, dATP, dCTP and dGTP pool levels when the HeLa + cells are incubated for 21 hours with 
different concentrations of LFM (0, 5, 50, 100 µM). The values in this table are calculated from the standard 
curves made in the same assay (figure 5) (n=1, but treated as three replicates). 
                dNTP     
Sample 
dTTP  
(pmol/2.106 cells) 
dATP  
(pmol/2.106 cells) 
dCTP  
(pmol/2.106 cells) 
dGTP  
(pmol/2.106 cells)  
+ 0 μM LFM   69.0±12.7** 123.2±0.9 72.6±11.7 47.3±3.1 
+ 5 µM LFM 74.4±25.9 (p=0.764) 133.1±10.3 (p=0.290) 61.0±17.6 (p=0.397) 29.9±3.1 (p=0.002) 
+ 50 µM LFM 33.1±21.6 (p=0.068) 85.5±6.0 (p=0.013) 61.3±10.2 (p=0.276) 26.0±6.2 (p=0.006) 
+ 100 µM LFM   28.6±1.2 (p=0.024) 57.7±5.4 (p=0.004) 71.0±12.6 (p=0.882) 29.3±5.5 (p=0.008) 
** Mean value±SD. 
 
Figure 6 Mean value±SD for the dTTP, dATP, dCTP and dGTP pools measured in pmol/106 cells in HeLa ρ+ cells 
treated with different concentrations of LFM (0, 5, 50, 100 µM) (n=1, but treated as three replicates). 
 3.2 Cell cycle distribution measured by FACS analysis 
The purpose of making the FACS analysis was to examine if the observed changes in the dNTP 
pool levels in the HeLa + cells treated with LFM was due to differences in the cell cycle 
distribution between the different cell samples. The FACS analysis was furthermore used to 
determine if different concentrations of LFM had an affect on the cell cycle distribution. 
For the FACS analysis the one LFM treated replicate was splitted to two FACS tubes as described in 
section 2.3.2 ‘The procedure for FACS analysis’. Since these two samples are from the same cell 
sample they are pseudo replicates. The two pseudo replicates will further on be considered as two 
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independent replicates. This is done in order to compare the effect of different LFM concentrations 
on the cell cycle distribution by students T-test analysis.  
 
The mean percentage values are calculated for each phase for the HeLa + and 143B TK- controls. 
One example is selected and shown in figure 7 and in appendix c ’FACS data’ are all data from the 
FACS analysis.  There are differences in the mean percentage of cells in the different cell cycle 
phases between HeLa + and 143 TK- controls (table 6). There was a 1.4 fold difference in the 
G0/G1 phase between HeLa + (59 %) and 143B TK- controls (41 %). In the S phase the difference 
was 1.4 fold between HeLa + (31 %) and 143B TK- controls (43 %). There was also a 1.5 fold 
difference in the G2/M phase between HeLa + (11 %) and 143B TK- controls (16 %).  
The differences between the cell cycle distributions could be due to their diverse abilities to 
synthesize dNTPs or that the cells were not synchronized.   
Table 6 Cell cycle distribution for HeLa + and 143B TK- controls (n=4).  
            Cell cycle phase 
Sample 
% in  G0/G1  % in S  % in G2/M 
HeLa + (control) 59* 30 11 
143B TK- (control) 41 43 16 
* Mean value  
 
Figure 7 Cell cycle distribution for HeLa wt (ρ+) controls and 143B TK- controls (n=4). The colored area under 
the curve is representative for the percentage of cells in the different cell cycle phases.  
According to figure 7 and 8 it is demonstrated that the cell cycle distribution for HeLa + controls 
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and for HeLa + cells (0 μM) are not the same as they were supposed to. The LFM treated HeLa + 
cells are therefore compared to the HeLa + cells (0 μM) and not to the HeLa + controls.  
 
The data in table 4 and figure 8 shows that LFM has an effect on the cell cycle distribution in HeLa 
+ cells. The HeLa + cells treated with 100 µM LFM accumulated in the G0/G1 phase when 
compared to the untreated HeLa + cells (0 µM) (table 4, figure 4). The accumulation was due to a 
1.1 fold (p=0.011) increase in the G0/G1 phase. When the HeLa + cells was treated with 50 µM 
LFM, the percentage of cells in the G0/G1 phase increased 1.1 fold (p=0.054) when compared to the 
HeLa + cells (0 µM) (table 4, figure 4). The treatment with 100 µM LFM demonstrates that the 
percentage of HeLa + cells decreased 1.1 fold (p=0.008) in the S phase and 1.4 fold (p=0.043) in 
the G2/M phase compared to HeLa + cells (0 µM). 5 µM LFM did not have an effect on the cell 
cycle distribution in HeLa + cells (table 4, figure 8). 
Table 7 Cell cycle distribution for HeLa ρ+ cells untreated with LFM (0 µM) or incubated with different 
concentrations of LFM (5, 50 and 100 µM) for 21 hours (n=1, but treated as two replicates). The p values are 
obtained by comparing the LFM treated HeLa + cells with the untreated HeLa + cells.   
            Cell cycle phase 
Sample 
% in  G0/G1  % in S  % in G2/M 
+ 0 µM LFM 53±0.5 * 34±0.2 14±0.9 
+ 5 µM LFM 54±2.1 (p=0.594) 34±0.5 (p=0.320) 12±1.6 (p=0.392) 
+ 50 µM LFM 59±2.1 (p=0.054) 29±1.5 (p=0.065) 12±0.6 (p=0.103) 
+ 100 µM LFM 58±0.7 (p=0.011) 31±0.1 (p=0.008) 10±0.6 (p=0.043) 
* Mean value±SD.   
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Figure 8 The cell cycle distribution for HeLa wt (ρ+) cells treated with different concentrations of LFM (0, 5, 50, 
100 µM) (n=1, but treated as two replicates). The colored area under the curve is representative for the 
percentage of cells in the different cell cycle phases.  
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 4 Discussion 
It has been demonstrated that HeLa cells with dysfunctional mitochondria (HeLa ρ0) have an 
imbalance in the dNTP pools and a substantial decrease in the dNTP pyrimidines as described in 
section 1.2 ’Dysfunctional mitochondria can cause an imbalance in the dNTP pools and thereby 
mutations’. The link between dysfunctional mitochondria and regulation of the dNTP pools are 
unknown. DHODHase has been suggested to be the link. 
This study was designed to examine if the DHODHase modulators LFM and A77 1726 could 
induce the same phenotype as cells with dysfunctional mitochondria with respect to the levels of 
dNTP pools.  
In vitro studies by Knecht & Löffler [1998] have demonstrated that LFM inhibits isolated human 
DHODHase with a low potency compared to A77 1726 or BQR. The present study is in vitro and is 
only carried out by the use of LFM and not by A77 1726 due to the time frame. LFM is metabolized 
in vivo to the active metabolite A77 1726 [Bartlett et al., 1991] and have also been demonstrated to 
be converted to in vitro to A77 1726 in microsomes to some extent [Kalgutkar et al., 2003]. It is not 
possible to exclude if LFM is converted to A77 1726 in the HeLa ρ+ cells. 
 4.1 dNTP pool levels in HeLa + and 143B TK- controls 
The distribution and size of the dNTP pool levels for HeLa + and 143B TK- controls were as 
described in section 3.1.2 ‘dNTP pool levels in HeLa +and 143B TK-controls’ not the same for the 
two cell lines. These differences can be due to several factors. The factors could be that different 
cell lines have different dNTP pool levels, that the 143B TK- cell line lacks the salvage pathway for 
synthesizing dNTP pyrimidines, and that the cell cycle distributions for HeLa + and 143B TK- 
controls were not the same. By synchronizing the cells it would be possible to avoid eventual 
differences in the dNTP pools caused by differences in the cell cycle distribution. 
 
To our knowledge the dNTP pool levels in 143B TK- cells have not been determined in other 
studies, and the results for the dNTP pool levels in this cell cannot be compared to other results. The 
order of the dNTP pool levels in the HeLa + controls determined in the present study was not the 
same as in other studies made by Desler et al. [2007] and North et al. [1980]. In addition to this it 
should be noted that Desler et al. [2007] and North et al. [1980] do not find the same dNTP pool 
order in HeLa + cells either. 
The differences in the dNTP pool levels between this study and the studies by Desler et al. [2007] 
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and North et al. [1980] can be due to the fact that an increasing amount of eluent was added in the 
present study. The ratio between eluent and Ultima Gold in the dNTP radio assay as described in 
section 3.1.1 ’CCPM values and standard curves for dNTP pool determinations’ were changed. 
Therefore, an exact determination of the dNTP pools was not obtained.    
 4.2 LFM has the greatest impact on the dNTP purines compared to 
the dNTP pyrimidines in HeLa + cells 
It is demonstrated that HeLa + cells treated with LFM have an imbalance in the dNTP pools, in 
which the dNTP purines are most sensitive. According to the FACS analysis the cell cycle 
distribution were affected by 100 µM LFM. It is possible that the observed dNTP pool differences 
between the LFM treated and the untreated HeLa + cells is not due to an effect of LFM but due to 
differences in the cell cycle distribution between the cell samples not caused by LFM. This source 
of error could be avoided by synchronizing the cells.  
 
Though, it should be noted, that the dNTP purine pool levels decreased statistically significant at 
lower concentrations than the concentrations that caused a statically significant change in the cell 
cycle distribution. The dATP pool level decreased 1.4 fold (p=0.013) at 50 µM and 2.1 fold 
(p=0.004) at 100 µM LFM, where the dGTP pool level decreased 1.6 (p=0.002), 1.8 (p=0.006) and 
1.6 (p=0.008) fold at 5, 50 and 100 µM LFM respectively compared to HeLa + cells (0 μM). This 
indicates that the changes in dATP and dGTP pool levels when the HeLa + cells are treated with 
LFM is not only due to differences in the cell cycle distribution between the cell samples but is also 
due to the effect of LFM.   
The increasing amount of added eluent could also have influenced the dNTP pool determination. 
Because of this fact it is not possible to deduce whether the observed dNTP pool changes in HeLa 
+ cells treated with LFM are only due to LFM or an incorrect dNTP pool measurement.      
 4.3 LFM treated HeLa + cells do not demonstrate a phenotype 
comparable to the phenotype in cells with dysfunctional 
mitochondria 
The purpose of this study was to examine if inhibition of DHODHase is accountable for the 
phenotype observed in cells with dysfunctional mitochondria characterised by an imbalance in the 
dNTP pool levels and a decrease in the dNTP pyrimidine pools. 
The dNTP purine pool levels in HeLa + cells were most sensitive to LFM treatment. Therefore, an 
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inhibition of DHODHase and thereby an inhibition of the de novo biosynthesis of dNTP 
pyrimidines by LFM do not cause a phenotype comparable to cells with dysfunctional mitochondria 
(HeLa ρ0) as expected. This indicates that DHODHase is not the link between dysfunctional 
mitochondria and a decrease in the dNTP pyrimidines. 
LFM has a low inhibitory potency with respect to DHODHase compared to A77 1726 [Knecht & 
Löffler, 1998]. It is not possible to exclude that A77 1726 treatment could induce an imbalance in 
the dNTP pools and a decrease in the dNTP pyrimidines comparable to the phenotype in cells with 
dysfunctional mitochondria. If A77 1726 would induce a comparable phenotype it would indicate 
that DHODHase is inhibited in ρ0 cells. It is possible that DHODHase is not only inhibited in ρ0 
cells but DHODHase could be incorrect imported and located. This is based on the fact that the 
import of DHODHase requires a mitochondrial membrane potential and ATP as described in section 
1.3.1 ’DHODHase’.  
 4.4 LFM induced affects on the cell cycle distribution not caused by 
an inhibition of DHODHase  
It is possible that other factors than DHODHase are affected if LFM is auto activated to A77 1726. 
A77 1726 has been shown to affect p53 [Mirmohammadsadegh et al., 1998] and epidermal growth 
factor receptor (EGFR) [Mattar et al., 1993]. These factors are involved in cell cycle progression 
[reviewed in Ryan et al., 2001; reviewed in Yarden, 2001].  
It has been demonstrated that the mRNA and protein levels of p53 were up regulated when a human 
epidermal cell line (HaCaT) was treated with A77 1726 [Mirmohammadsadegh et al., 1998]. 
Activation of p53 can induce several cellular responses e.g. cell cycle arrest in the G1 phase and 
apoptosis [reviewed in Levine, 1997; reviewed in Ryan et al., 2001]. It is possible that LFM via 
auto activation to A77 1726 can up regulate the p53 mRNA and protein levels in the present study 
and thereby arrest the cells in the G1 phase.  
EGFR is involved in cell proliferation and differentiation [reviewed in Yarden, 2000]. Mattar et al. 
[1993] have demonstrated that the autophosphorylation of EGFR and the cell proliferation in human 
foreskin fibroblast cells were inhibited by A77 1726 [Matter et al., 1993]. Since HeLa + cells also 
have EGFR [Galperin & Sorkin, 2008] it is possible, that the EGFR is inhibited in the HeLa + cells 
treated with LFM and thereby induce cell cycle arrest. 
 
100 μM LFM caused a statistically significant accumulation of cells in the G0/G1 phase. It cannot be 
determined whether or not this cell accumulation is due to an inhibition of EGFR or a change in the 
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p53 level caused by A77 1726 derived from LFM.  
 4.5 Other factors than inhibition of DHODHase that could affect the 
level of dNTP pools 
There are other potential ways that the mitochondria can regulate the dNTP pools than by 
DHODHase.  
A possible explanation, that links mitochondrial dysfunction and an imbalance in the total dNTP 
pools, is the impaired production of ATP [Desler et al., 2007]. It has been demonstrated that HeLa 
ρ0 and breast cancer cells devoid of mtDNA (MDAMB435 ρ0) have a decreased ATP level 
compared to the respective + cells. The two cell lines had furthermore an imbalance in the dNTP 
pools characterized by decreases in the dNTP pool levels. Because the changes in the ATP and 
dNTP levels were not identical in the two cell lines it seem like that there are other mitochondrial 
processes than ATP, that are contributing to the observed dNTP pool imbalances [Desler et al., 
2007]. 
Mitochondria are not only involved in the de novo biosynthesis of pyrimidines but also in the de 
novo biosynthesis of purines. They produce a one-carbon unit (formate) in a NAD+ dependent 
reaction. The formate can be transported from the mitochondria to the cytosol where it can be 
converted to 10-formyltetrahydrofolate (10-CHO-TFH) in an ATP dependent reaction. 10-CHO-
TFH is an essential one-carbon donor for the de novo biosynthesis of purines [reviewed in Depeint 
et al., 2006]. An opening of the mitochondrial permeability transition pore (PT pore) by e.g. 
depolarization of the mitochondrial membrane [reviewed in Bernardi et al., 1994], which is 
characteristic for cells with dysfunctional mitochondria [Porcelli et al., 2009], causes a depletion of 
NAD+ in the mitochondria [Di Lisa et al., 2001]. The NAD+ dependent reaction in which formate is 
produced is also suggested to be sensitive to the ATP/ADP ratio in the matrix [Patel et al., 2003]. It 
is therefore possible that mitochondrial dysfunction leading to decreased ATP level as seen in 
Desler et al. [2007] can change the ATP/ADP ratio in the mitochondrial matrix and thereby inhibit 
the production of formate.  
In addition to this it has been demonstrated that 100 µM LFM decreases the membrane potential in 
143B TK- cells [Spodnik et al., 2002]. A depolarization of the inner mitochondrial membrane could 
lead to opening of the PT pore and depletion of mitochondrial NAD+ and a decrease in the ATP 
synthesis. An impairment of the de novo biosynthesis of purines caused by depolarization of the 
inner mitochondrial membrane by LFM fits with the present results, where a decrease in both dATP 
and dGTP is observed when the HeLa + cells are treated with LFM.  
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 5 Conclusion 
The aim of this study was to examine if an inhibition of DHODHase causes the observed phenotype 
observed in cells with dysfunctional mitochondria (ρ0) characterized by an imbalance in the dNTP 
pools and a decrease in the dNTP pyrimidines.  
HeLa + cells treated with the DHODHase modulator LFM exhibited an imbalance in the dNTP 
pools and a most prominent decrease in the dNTP purine pools. These results do not correspond to 
the ρ0 phenotype. Based on the results obtained in the present study it is not possible to confirm if 
an inhibition of DHODHase is linked to an imbalance in the dNTP pools and a decrease in the 
dNTP pyrimidines. Though, LFM has a low inhibitory potency in respect to DHODHase and it is 
possible that a more potent inhibitor of DHODHase like A77 1726 could cause an imbalance in the 
dNTP pools and a decrease in the dNTP pyrimidines.  
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 6 Future studies 
Future studies could include an examination of the effect of LFM and A77 1726 on HeLa ρ0 cells in 
respect to the dNTP pool levels. By including the ρ0 cells it would be possible to observe if LFM 
and A77 1726 changes the dNTP pool levels in cells with dysfunctional mitochondria. If the dNTP 
pools are changed in the ρ0 cells DHODHase is probably not implicated in the decrease of dNTP 
pyrimidines in HeLa ρ0 cells.  
Furthermore, enzyme kinetic experiments could be included in which the activity of DHODHase is 
examined in the presence of LFM and A77 1726 or without. This should also be done in HeLa +, 
143B TK-, and HeLa ρ0 cells. By the use of enzyme kinetics it would be possible to determine the 
inhibitory potency of LFM and A77 1726 with respect to DHODHase.  
 
     
   
32 
 
33 
 
 7 Literature 
Ahluwalia, G.S., W.-Y. Gao, H. Mitsuya  & D. G. Johns (1996): 2’,3’-Didehydro-3’deoxythymidine: 
Regulation of its Metabolic Activation by Modulators of Thymidine-5’-triphosphate Biosynthesis, 
Molecular Pharmacology. 50:160-165 
 
Bader, B., W. Knecht, M. Fries & M. Löffler (1998): Expression, Purification, and Characterization 
of Histidine-Tagged Rat and Human Flavoenzyme Dihydroorotate Dehydrogenase, Protein 
expression and purification. 13:414-422 
Bartlett, R.R., M. Dimitrijevic, T. Mattar, T. Zielinski, T. Germann, E. Rüde, G.H. Thoenes, C. C.A. 
Kiichle, H.-U. Schorlemmer, E. Bremer, A. Finnegan & R. Schleyerbach (1991): “Leflunomide 
(HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and 
reactions leading to transplantation rejection”, Agents and Actions. 32(1/2):10-21  
 
Bebenek, K. & T.A. Kunkel (1990): Frameshift errors initiated by nucleotide misincorporation, 
Proc. Natl. Acad. Sci. 87: 4946-4950 
 
Bernardi, P., K.M. Broekemeier & D.R. Pfeiffer (1994): Recent Progress on Regulation of the 
Mitochondrial Permeability Transition Pore; a Cyclosporin-Sensitive Pore in the Inner 
Mitochondrial Membrane, Journal of Bioenergetics and Biomembranes.  26(5): 509-517 
 
Birch-Machin, M. A. (2006): The role of mitochondria in ageing and carcinogenesis, Clinical and 
Experimental Dermatology. 31: 548–552 
 
Chen, J.J. & M.E. Jones (1976): The cellular location of dihydroorotate dehydrogenase: Relation to 
de novo biosynthesis of pyrimidines, Archives of biochemistry and biophysics. 176: 82-90 
 
Chen, S.-F., F.W. Perrella, D.L. Behrens & L.M. Papp (1992): Inhibition of Dihydroorotate 
Dehydrogenase Activity by Brequinar Sodium, Cancer Research. 52: 3521-3527  
 
Cherwinski, H.M., D. McCarley, R. Schatzman, B. Devens & J.T. Ransom (1995a): The 
Immunosuppresant Leflunomide Inhibits Lymphocyte progression Through Cell Cycle by a Novel 
Mechanism, The Journal of Pharmacology and Experimental Therapeutics. 272:460-468 
 
Cherwinski, H.M., N. Byars, S.J. Ballaron, G.M. Nakano, J.M Young & J.T. Ransom (1995b): 
Leflunomide interferes with pyrimidine nucleotide biosynthesis, Inflammation Research. 44:317-322  
 
Copeland, R.A., J.P. Davis, R.L. Dowling, D. Lombardo, K.B. Murphy & T.A. Patterson (1995):  
Recombinant Human Dihydroorotate Dehydrogenase: Expression, Purification, and 
Characterization of a Catalytically Functional Truncated Enzyme, Archives of Biochemistry and 
Biophysics. 323(1):79-86 
 
Cummins, J. (1998): Mitochondrial DNA in mammalian reproduction, Reviews of Reproduction. 3: 
172–182 
 
Davis, J.P., G.A. Cain, W.J. Pitts, R.L. Magolda & R.A. Copeland (1996): The Immunosuppressive 
Metabolite of Leflunomide Is a Potent Inhibitor of Human Dihydroorotate Dehydrogenase, 
34 
 
Biochemistry. 35:1270-1273 
 
Deitch, A.D., H. Law & R. D. White (1982): A Stable Propidium Iodide Staining Procedure for 
Flow Cytometry, Journal of Histochemistry and Cytochemistry. 
30( 9): 967-972 
 
Depeint, F., W.R. Bruce, N. Shangari, R. Mehta & P.J. O’Brien (2006): Mitochondrial function and 
toxicity: Role of B vitamins on the one-carbon transfer pathways, Chemico-Biological Interactions. 
163: 113–132 
 
Desler, C.M., B. Munch-Petersen, T. Stevnsner, S.-I. Matsui, M. Kulawiec, K.K. Singh & L.J. 
Rasmussen (2007): Mitochondria as determinant of nucleotide pools and chromosomal stability, 
Mutation Research. 625:112-124 
Di Lisa, F., R. Menabo, M. Canton, M. Barile & P. Bernardi (2001): Opening of the Mitochondrial 
Permeability Transition Pore Causes Depletion of Mitochondrial and Cytosolic NAD+ and Is a 
Causative Event in the Death of Myocytes in Postischemic Reperfusion of the Heart, The journal of 
biological chemistry. 276(4): 2571–2575 
 
Evans, D.R. & H.I. Guy (2004): Mammalian Pyrimidine Biosynthesis: Fresh Insights into an 
Ancient Pathway. 279(32): 33035-33038 
 
fermentas.com: Date: 21.05.2009   10:15 AM UTC/GMT +1 hour 
http://www.fermentas.com/catalog/modifyingenzymes/klenowfragment.htm 
 
Galperin, E. & A. Sorkin (2008): Endosomal Targeting of MEK2 Requires RAF, MEK Kinase 
Activity and Clathrin-Dependent Endocytosis, Traffic. 9: 1776–1790 
 
Greene, S., K. Watanabe, J. Braatz-Trulson & L. Lou (1995): Inhibition of dihydrooroate 
dehydrogenase by the immunosuppressive agent leflunomide, Biochemical Pharmacology. 
50(6):861-867  
 
Jallepalli, P.V. & C. Lengauer (2001): Chromosome segregation and cancer: cutting through the 
mystery, Nature Reviews Cancer. 1:109-117  
 
Kalgutkar, A.S., H.T. Nguyen, A.D. N. Vaz, A. Doan, D.K. Dalvie, D.G. Mcleod & J.C. Murray 
(2003): In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent 
leflunomide to its active _-cyanoenol metabolite a771726: mechanistic similarities with the 
cytochrome p450-catalyzed dehydration of aldoximes, Drug Metabolism and Disposition. 
31(10):1240-1250 
 
Knecht, W. & M. Löffler (2000): Inhibition and localization of human and rat dihydrogenase, 
Advances in experimental medicine and biology. 486: 267-270 
  
Knecht, W. & M. Löffler (1998): Species-related Inhibition of Human Rat Dihydroorotate 
Dehydrogenase by Immunosuppressive Isoxasol and Cinchonic Acid Derivates, Biochemical 
Pharmacology. 56:1259-1264 
 
35 
 
Knecht, W., J. Henseling & M. Löffler (2000): Kinetics of inhibition of human and rat 
dihydroorotate dehydrogenase by atovaquone, lawsome derivates, brequinar sodium and polyporic 
acid, Chemico-Biological Interaction. 124:61-76 
 
Kulawiec, M., A. Safina, M.M. Desouki, I. Still, S. Matsui, A. Bakin & K.K. Singh (2008): 
Tumorigenic transformation of human breast epithelial cells induced by mitochondrial DNA 
depletion, Cancer Biology & Therapy. 7:1732-1743 
 
Larsen, N.B., M. Rasmussen & L.J. Rasmussen (2005): Nuclear and mitochondrial DNA repair: 
similar pathways?, Mitochondrion 5: 89–108 
 
Lee, H.-C. & Y.-H. Wei (2007): Oxidative stress, mitochondrial DNA mutation, and apoptosis in 
aging, Exp Biol Med. 232: 592–606 
 
Levine, A.J. (1997): p53, the Cellular Gatekeeper for Growth and Division, Cell. 88: 323–331 
 
Liu, S., E.A. Neidhardt, T.H. Grossman, T. Ocain & J. Clardy (2000): Structures of human 
dihydroorotate dehydrogenase in complex with antiproliferative agents, Structure. 8:25-33 
 
Löffler, M., J. Jöckel, G. Schuster & C. Becker (1997): Dihydroorotat-ubiquinone oxidoreductase 
links mitochondria in the biosynthesis of pyrimidine nucleotides, Molecular and Cellular 
Biochemistry. 174: 125-129 
Mathews, C.K. & S. Song (2007): Maintaining precursor pools for mitochondrial DNA Replication, 
FASEB J. 21: 2294 –2303. 
 
Mattar, T., K. Kochhar, R. Bartlett, E. G. Bremer & A. Finnegan (1993): Inhibition of the epidermal 
growth factor receptor tyrosine kinase activity by leflunomide, Febs Letters. 334(2): 161-164 
 
Mirmohammadsadegh, A., B. Homey, H. F. Abts, K. Köhrer, T. Ruzicka & G. Michel (1998): 
Differential Modulation of Pro- and Antiinflammatory 
Cytokine Receptors by N-(4-Trifluoromethylphenyl)-2-Cyano-3-Hydroxy-Crotonic 
Acid Amide (A77 1726), the Physiologically Active Metabolite of the Novel Immunomodulator 
Leflunomide, Biochemical Pharmacology. 55: 1523–1529 
 
Modica-Napolitano, J. S. & K.K. Singh (2002): Mitochondria as targets for detection and treatment 
of cancer, Molecular Medicine. Expert Reviews 2002:1-19  
 
Modica-Napolitano, J. S. & K.K. Singh (2004): Mitochondrial dysfunction in cancer, 
Mitochondrion. 4:755-762 
 
Munch-Petersen, B., Prof. (2009): Personal Communication, Department of Science, Systems and 
Models, Roskilde University, Denmark  
 
Nair, R.V., W. Cao & R.E. Morris (1995): Inhibition of smooth muscle cell proliferation in vitro by 
leflunomide, a new imunnosupressant, is anatonized by uridine, Immunlogy Letters. 47:171-174 
 
Nelson, D. L. & M. M. Cox (2005): Lehninger Principles of Biochemistry, W. H. Freeman & 
36 
 
Company. 4th Edition. New York 
 
Nicander, B. & P. Reichard (1983): Dynamics of pyrimidine deoxynucleoside triphosphate pools in 
relationship to DNA synthesis in 3T6 mouse fibroblasts, Cell biology. 80: 1347-1351. 
 
North, T.W., R.K. Bestwick & C. K. Mathews (1980): Detection of Activities that Interfere with the 
Enzymatic Assay of Deoxyribonucleoside 5’-Trophosphates, The Journal of Biological Chemistry. 
255(14): 6640-6645 
 
Nunez, R. (2001): DNA Measurement and Cell Cycle Analysis by Flow Cytometry, Curr. Issues 
Mol. Biol. 3(3): 67-70 
 
Patel, H., E. Di Pietro & R. E. MacKenzie (2003): Mammalian fibroblasts lacking mitochondrial 
NAD+ -dependent methylenetetrahydrofolate dehydrogenase-cyclohydrolase are glycine 
auxotrophs, The journal of biological chemistry. 278(21): 19436–19441 
 
Pelicano, H., D. Carney & P. Huang (2004): ROS stress in cancer cells and therapeutic 
implications, Drug Resistance Updates. 7: 97–110 
 
Penta, J.S., F.M. Johnson, J.T. Wachsman & W.C. Copeland (2001): Mitochondrial DNA in human 
malignancy, Mutation Research. 488: 119–133 
 
Porcelli, A.M., A. Angelin, A. Ghelli, E. Mariani, A. Martinuzzi, V. Carelli, V. Petronilli, P. Bernardi 
& M. Rugolo (2009): Respiratory Complex I Dysfunction Due to Mitochondrial DNA Mutations 
Shifts the Voltage Thresshold for Opening of the Permeability Transition Pore toward Resting 
Levels, The Journal of Biological Chemistry. 284(4): 2045-2052 
 
Rawls, J., W. Knecht, K. Diekert, R. Lill & M. Löffler (2000): Requirements for the mitochondrial 
import and localization of dihydroorotate dehydrogenase, European Journal of biochemistry. 
267:2079-2087 
Reichard, P. (1988): Interactions Between Deoxyribonucleotide and DNA Synthesis, Annual 
Reviews Biochemistry. 57: 349-374 
 
Ryan, K.M., A.C. Phillips & K. H. Vousden (2001): Regulation and function of the p53 tumor 
suppressor protein, Current Opinion in Cell Biology. 13: 332–337 
 
Rückemann, K., L.D. Fairbanks, E.A. Carrey, C.M. Hawrylowicz, D.F. Richards, B. Kirschbaum & 
H.A. Simmonds (1998): Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-stimulated 
T-lymphocytes from Healthy Humans, The journal of biochemical chemistry. 273(34): 21682-21691 
 
Sherman, P.A. & J.A. Fyfe (1989): Enzymatic Assay for Deoxyribonucleoside Triphosphates Using 
Synthetic Oligonucleotides as Template Primers, Analytical Biochemistry. 180: 222-226 
 
Silva, Jr. H.T., W. Cao, R.A. Shorthouse, M. Löffler & R.E. Morris (1997): In Vitro and In Vivo 
Effects of Leflunomide, Brequinar, and Cyclosporine on Pyrimidine Biosynthesis, Transplantation 
Proceedings. 29: 1292-1293     
 
37 
 
Singh, K.K. (2004): Mitochondria damage checkpoint in apoptosis and genome stability, FEMS 
Yeast Research. 5:127-132 
 
Singh, K.K., M. Kulawiec, I. Still, M.M. Desouki, J. Geradts & S.-I. Matsui (2005): Inter-genomic 
cross talk between mitochondria and the nucleus plays an important role in tumorigenesis, Gene. 
354:140-146     
 
Singh, K.K. (2006): Mitochondria damage checkpoint, aging, and cancer, Annals New York 
Academy of Sciences. 1067: 182–190 
 
Solter, A.M. & R.E. Handschumacher (1969): A rapid quantitative determination of 
deoxyribonucleoside triphosphates based on the enzymatic synthesis of DNA, Biochimica Et 
Biophysica Acta. 174: 585-590  
 
Song, S., L.J. Wheeler & C.K. Matthews (2003): Deoxyribonucleotide Pool Imbalance Stimulates 
Deletions in HeLa Cell Mitochondrial DNA, The Journal of Biological Chemistry. 278(45): 43893–
43896 
 
Spodnik, J.H.,  M. Wozniak, D. Budzko, M.-A. Teranishi, M. Karbowski, Y. Nishizawa, J. Usukura, 
T. Wakabayashi (2002): Mechanism of leflunomide-induced proliferation of mitochondria in 
mammalian cells, Mitochondrion. 2: 163–179 
 
Traut, T.W. (1994): Physiological concentrations of purines and pyrimidines, Molecular and 
Cellular Biochemistry. 140: 1-22 
 
von Kleist-Retzow, J.-C., U. Schauseil-Zipf, D.V. Michalk & W.S. Kunz (2003): Mitochondrial 
diseases – an expanding spectrum of disorders and affected genes, Experimental Physiology. 88(1): 
155-166   
 
Wickremasinghe, R. G.  & A.V. Hoffbrand (1980): Reduced rate of DNA replication fork movement 
in megaloblastic anemia, The American Society for Clinical Investigation. 65: 26-36 
 
Williamson, R.A., C.M. Yea, P.A. Robson, A.P. Curnock, S. Gadher, A.B. Hambleton, K. 
Woodward, J.-M. Bruneau, P. Hambleton, D. Moss, T.A. Thomson, S. Spinella-Jaegle, P. Morand, 
O. Courtin, C. Sautés, R. Westwood, T. Hercend, E.A. Kuo & E. Ruuth (1995): Dihydrooratate 
Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of 
Biological Effects of the Immunomodulatory Compound, The Journal of Biological Chemistry. 
270(38): 22467-22472   
 
Yamato, M., Y. Hirota, S. Yoshida, S. Tanaka, T. Morita, J. Sakai, K. Hashigaki, H. Hayatsu & Y. 
Wataya (1992): Imbalance of Deoxyribonucleoside Triphosphates and DNA Double-strand Breaks 
in Mouse Mammary Tumor FM3A Cells Treated in vitro with an Antineoplastic Tropolone 
Derivative, Jpn. J. Cancer Res. 83: 661-668 
 
Yarden, Y. (2001): Biology of HER2 and Its Importance in Breast Cancer, Oncology 61(suppl 2):1-
13  
 
Zielinski, T., D. Zeitter, S. Müllner & R.R. Bartlett (1995): Leflunomide, a reversible inhibitor of 
38 
 
pyrimidine biosynthesis?, Inflammation Research. 44: Supplement 2 207-208 
 
 
39 
 
Appendix 
 a Raw data 
Table 2 CCPM values for the different dNTPs for HeLa ρ+ controls. Values in [ ] is left out from the mean and SD 
calculations. 
dTTP 
HeLa ρ+ 
control 
143B TK- 
control dATP 
HeLa ρ+ 
control 
143B TK- 
control 
A 538 397 a 4022 1214 
B 746 589 b 5036 1183 
C 566 363 c 3841 1058 
D 388 557 d 5960 1481 
E 512 521 e 4332 1693 
F 550 490 f 4569 2052 
G 357 434 g 2122 2141 
H 417 546 h 2453               [889] 
I 509 683 i 3165 1638 
J 321 584 j 4861 1167 
K 689 753 k 2210 2076 
L 510 518 l 4113 2036 
Mean 511 533.5 Mean 4067.5 1612.63 
SD 126.4555 111.4655 SD 1198.7051 417.1681 
      
dCTP 
HeLa ρ+ 
control 
143B TK- 
control dGTP 
HeLa ρ+ 
control 
143B TK- 
control 
A 1357 276 a 400 393 
B 903 324 b 424 448 
C 1543 268 c 362               [137] 
D 1173 332 d 360 689 
E 1341 315 e 316 518 
F 1355 367 f 311 416 
G 735 315 g 208 639 
H 507 303 h 236 695 
I 758 293 i 238 659 
J 1062 375 j 248 502 
K 880 406 k 281 659 
L 772 383 l 229 678 
Mean 982.5 319.5 Mean 296 572.36 
SD 321.0199 44.0312 SD 72.4211 118.0036 
 
Table 3 CCPM values for the different dNTPs for standard curves for HeLa ρ+ cells treated with LFM and 143B 
TK- controls. Values in [ ] is left out from the mean and SD calculations. 
dTTP standard curve (143B 
TK- + HeLa ρ+ treated with 
LFM) 0 pmol 2 pmol 5 pmol 10 pmol 
A 206 358 623 682 
B 212 367 736         [444] 
C 238          [591]        [1103] 1093 
Mean 212 362.5 679.5 887.5 
SD 17.0098 6.364 79.9031 290.6209 
     
dATP standard curve (143B 0 pmol 2 pmol 5 pmol 10 pmol 
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TK- + HeLa ρ+ treated with 
LFM) 
A 104 362 1302        [1646] 
B 122 347        [2138] 2024 
C 133          [499] 1695        [1514] 
Mean 122 354.5 1498.5 2024 
SD 14.6401 10.6066 277.893                - 
     
dCTP standard curve (143B 
TK- + HeLa ρ+ treated with 
LFM) 0 pmol 2 pmol 5 pmol 10 pmol 
A 107 181          [656]         [310] 
B 92 339 200 609 
C 119 282 348 435 
Mean 107 282 274 522 
SD 13.5277 80.0146 104.6518 123.0366 
     
dGTP standard curve (143B 
TK- + HeLa ρ+ treated with 
LFM) 0 pmol 2 pmol 5 pmol 10 pmol 
A          [541]          [418] 461 648 
B 112 225 274 594 
C 128 260 261        [1450] 
Mean 120 242.5 274 621 
SD 11.3137 24.7487 111.9062 38.1838 
 
Table 4 CCPM values for the different dNTPs for standard curves for HeLa ρ+ controls. Values in [ ] is left out 
from the mean and SD calculations. 
dTTP standard curve (HeLa 
ρ+) 0 pmol 2 pmol 5 pmol 10 pmol 
A 67 196 527 1498 
B 108 331 733 717 
C 79 340         [287] 1969 
Mean 79 331 630 1498 
SD 21.0792 80.666 145.664 632.3641 
     
dATP standard curve (HeLa 
ρ+) 0 pmol 2 pmol 5 pmol 10 pmol 
A 132 600 2344 3642 
B 165 760 1710 4238 
C 138 866 1196 2894 
Mean 138 760 1710 3642 
SD 17.5784 133.9104 575.0443 673.4310 
     
dCTP standard curve (HeLa 
ρ+) 0 pmol 2 pmol 5 pmol 10 pmol 
A 107 405         [410] 1162 
B 115 375 590 977 
C 142 534 886 1996 
Mean 115 405 738 1162 
SD 18.3394 84.4808 209.3036 542.8539 
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dGTP standard curve (HeLa 
ρ+) 0 pmol 2 pmol 5 pmol 10 pmol 
A 39 109 295 417 
B 67 136 240 381 
C 59 131 277 664 
Mean 59 131 277 417 
SD 14.4222 14.3643 28.0416 154.0530 
 
Table 5 CCPM values for the different dNTPs for HeLa ρ+ cells treated with different concentrations of LFM. 
Values in [ ] is left out from the mean and SD calculations. 
dTTP (HeLa ρ+ + 
LFM) 0 uM 5 uM 50 uM 100 uM 
a 823 643 384 460 
b 666 957 653 471 
c 698 692 448         [683] 
Mean 698 692 448 465.5 
SD 82.9638 168.929 140.5240 7.7782 
Ttest           0.764         0.068         0.024 
     
dATP (HeLa ρ+ + 
LFM) 0 uM 5 uM 50 uM 100 uM 
a 2641 2902       [2832] 1228 
b 2615 2592 1952 1383 
C       [1771] 2985 1781       [2131] 
Mean 2628 2902 1866.5 1305.5 
SD 18.3848 207.1384 120.9153 109.6016 
Ttest           0.290         0.013         0.004 
     
dCTP (HeLa ρ+ + 
LFM) 0 uM 5 uM 50 uM 100 uM 
a 357 307 336 352 
b 443 344 408 448 
C 420 437 347 402 
Mean 420 344 347 402 
SD 44.5234 66.9801 38.7857 48.0139 
Ttest           0.397         0.276         0.882 
     
dGTP (HeLa ρ+ + 
LFM) 0 uM 5 uM 50 uM 100 uM 
a 354 267 222 258 
b 336 253 243 242 
C 366 283 281 294 
Mean 354 267 243 258 
SD 15.0997 15.0111 29.9054 26.6333 
Ttest           0.002         0.006         0.008 
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 b Standard curves 
 
Figure 1 Standard curves for dTTP, dATP, dCTP and dGTP for HeLa ρ+ controls. 
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Figure 2 Standard curves for dTTP, dATP, dCTP and dGTP for 143B TK- controls and HeLa ρ+ cells treated with 
different concentrations of LFM. 
 b.a Calculation from CCPM to pmol/106 cells 
The dNTP pool levels are determined in pmol/106 cells by use of the standard curves. Below is an 
example on how to calculate the level of the dTTP pool for the HeLa + cells treated with 100 μL 
LFM. The mean CCPM value for this sample is 465.5 (Appendix a, table 4) and the equation for the 
corresponding standard curve is y = 65.13x + 279.2 (figure 2).  
x is isolated in the standard curve equation as below:  
 
(y – 279.2)/65.13 =  x pmol/105 cells 
 
The CCPM value (465.5) for the sample is inserted in the equation instead of y: 
 
(465.5 – 279.2)/65.13 = 2.86 pmol/106 cells 
 
The above dTTP pool level is for 105 cells and is therefore multiplied with 10:  
 
10  2.86 pmol/105 cells = 28.6 pmol/106 cells 
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 c FACS data 
Figure 3 HeLa wt (ρ+) + 0 μM LFM – sample 1 
Figure 4 HeLa wt (ρ+) + 0 μM LFM – sample 2 
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Figure 5 HeLa wt (ρ+) + 5 μM LFM sample 1 
 
Figure 6 HeLa wt (ρ+) + 5 μM LFM – sample 2 
46 
 
 
Figure 7 HeLa wt (ρ+) + 50 μM LFM – sample 1 
Figure 8 HeLa wt (ρ+) + 50 μM LFM sample 2 
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Figure 9 HeLa wt (ρ+) + 100 μM LFM – sample 1 
Figure 10 HeLa wt (ρ+) + 100 μM LFM – sample 2 
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Figure 11 HeLa wt (ρ+) control – sample 1 
 
Figure 12 HeLa wt (ρ+) control – sample 2 
49 
 
Figure 13 HeLa wt (ρ+) control – sample 3 
Figure 14 HeLa wt (ρ+) control – sample 4 
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Figure 15 HeLa wt (ρ+) control – sample 5 
Figure 16 HeLa wt (ρ+) control – sample 6 
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Figure 17 HeLa wt (ρ+) control – sample 7  
Figure 18 HeLa wt (ρ+) control – sample 8 
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Figure 19 143B TK- control – sample 1 
 
Figure 20 143B TK- control – sample 2 
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Figure 21 143B TK- control – sample 3 
 
Figure 22 143B TK- control – sample 4 
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Figure 23 143B TK- control – sample 5 
 
Figure 24 143B TK- control – sample 6 
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Figure 25 143B TK-  control – sample 7 
 
Figure 26 143B TK-  control – sample 8 
 
